problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl13075problendo-13075Research ArticleКлиническая эндокринологияClinical endocrinologyОпыт применения терипаратида для лечения послеоперационного гипопаратиреоза у пациентов, получающих заместительную почечную терапию программным гемодиализомExperience in using teriparatide for the treatment of postoperative hypoparathyroidism in hemodialysis patientshttps://orcid.org/0000-0001-6667-062XЕремкинаА. К.EremkinaA. K.

Еремкина Анна Константиновна – кандидат медицинских наук.

117036, Москва, ул. Дмитрия Ульянова, д. 11.

SPIN-код: 8848-2660

Anna K. Eremkina - MD, Ph.D.

11, Dm.Ul’yanova street, 117036 Moscow.

SPIN-код: 8848-2660

eremkina.anna@endocrincentr.ruhttps://orcid.org/0000-0001-6581-4521ГорбачеваА. М.GorbachevaA. M.

Горбачева Анна Максимовна.

117036, Москва, ул. Дмитрия Ульянова, д. 11.

SPIN-код: 4568-4179

Anna M. Gorbacheva - MD.

11, Dm.Ul’yanova street, 117036 Moscow.

SPIN-код: 4568-4179

gorbacheva.anna@endocrincentr.ruhttps://orcid.org/0000-0002-7579-7988ЕненкоВ. А.EnenkoV. A.

Ененко Валерия Анатольевна.

Москва.

Valeriya A. Enenko – MD.

Moscow.

valeriya.enenko.94@mail.ruhttps://orcid.org/0000-0003-4830-0152ЛитвиноваЕ. Е.LitvinovaE. E.

Литвинова Елена Евгеньевна.

117036, Москва, ул. Дмитрия Ульянова, д. 11.

Elena E. Litvinova – MD.

11, Dm.Ul’yanova street, 117036 Moscow.

litvinova.elena@endocrincentr.ruhttps://orcid.org/0000-0002-9717-9742МокрышеваН. Г.MokryshevaN. G.

Мокрышева Наталья Георгиевна – доктор медицинских наук, профессор.

117036, Москва, ул. Дмитрия Ульянова, д. 11.

SPIN-код: 5624-3875

Natalia G. Mokrysheva - MD, PhD, Professor.

11, Dm.Ul’yanova street, 117036 Moscow.

SPIN-код: 5624-3875

parathyroid.enc@gmail.comНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CenterRussian FederationКлиника «Семейная»Россия«Semeynaya» ClinicRussian Federation2022300520226843039Copyright © Еремкина А.К., Горбачева А.М., Ененко В.А., Литвинова Е.Е., Мокрышева Н.Г., 20222022Еремкина А.К., Горбачева А.М., Ененко В.А., Литвинова Е.Е., Мокрышева Н.Г.Eremkina A.K., Gorbacheva A.M., Enenko V.A., Litvinova E.E., Mokrysheva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/13075

Частота хронического послеоперационного гипопаратиреоза при выполнении тотальной паратиреоидэктомии по поводу вторичного и третичного гиперпаратиреоза у пациентов с терминальной почечной недостаточностью, по данным различных авторов, может достигать 20% и более. На фоне приема активных метаболитов витамина D, препаратов кальция не всегда удается достичь целевых значений кальция, поэтому возникает необходимость применения заместительной терапии рекомбинантным паратгормоном. Единственным препаратом данного ряда, одобренным и разрешенным Американским Агентством по контролю за пищевыми продуктами и медикаментами (FDA) и зарегистрированным в Российской Федерации, является терипаратид. Однако он зарегистрирован как анаболический антиостеопоретический препарат и не показан для лечения хронического гипопаратиреоза. Применение терипаратида при послеоперационном гипопаратиреозе у пациентов, получающих заместительную почечную терапию программным гемодиализом в Российской Федерации, ранее не изучалось, лимитированы данные по этому вопросу и в зарубежной литературе. Тем не менее это потенциальный вариант лечения гемодиализных пациентов с хроническим гипопаратиреозом и тяжелыми костными нарушениями. В настоящей статье будут рассмотрены 2 клинических случая, демонстрирующих возможности заместительной и анаболической терапии терипаратидом в данной когорте больных.

The frequency of chronic postoperative hypoparathyroidism after total parathyroidectomy for secondary and tertiary hyperparathyroidism in patients with end-stage renal failure, according to various authors, can reach 20% or more. Prescribing active metabolites of vitamin D and calcium it is not always sufficient for achievement of target goals. This dictates the need for replacement therapy with recombinant parathyroid hormone. Teriparatide is the only drug of this series approved by the American Food and Drug Administration (FDA) and registered in the Russian Federation. However, it is registered as an anabolic anti-osteoporotic drug and is not indicated for the treatment of chronic hypoparathyroidism. The use of teriparatide in postoperative hypoparathyroidism in patients receiving renal replacement therapy with programmed hemodialysis in the Russian Federation has not been previously studied. Data on this issue is also limited in foreign literature. However, it is a potential treatment option for hemodialysis patients with chronic hypoparathyroidism and severe bone disorders. In this article, we present 2 clinical cases of substitution and anabolic therapy with teriparatide in this cohort of patients.

гемодиализгипопаратиреозтерипаратидостеопорозклинический случайhemodialysishypoparathyroidismteriparatideosteoporosiscase reportsРабота проведена в рамках выполнения Государственного задания Минздрава России (АААА-А20-120011790168-2).ReferencesLevey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100. doi: https://doi.org/10.1111/j.1523-1755.2005.00365.xLevey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-2100. doi: https://doi.org/10.1111/j.1523-1755.2005.00365.xHedgeman E, Lipworth L, Lowe K, et al. International Burden of Chronic Kidney Disease and Secondary Hyperparathyroidism: A Systematic Review of the Literature and Available Data. Int J Nephrol. 2015;2015:1-15. doi: https://doi.org/10.1155/2015/184321Hedgeman E, Lipworth L, Lowe K, et al. International Burden of Chronic Kidney Disease and Secondary Hyperparathyroidism: A Systematic Review of the Literature and Available Data. Int J Nephrol. 2015;2015:1-15. doi: https://doi.org/10.1155/2015/184321Cozzolino M, Shilov E, Li Z, et al. Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America. Adv Ther. 2020;37(6):2748-2762. doi: https://doi.org/10.1007/s12325-020-01359-1Cozzolino M, Shilov E, Li Z, et al. Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America. Adv Ther. 2020;37(6):2748-2762. doi: https://doi.org/10.1007/s12325-020-01359-1Rodriguez M, Caravaca F, Fernandez E, et al. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int. 1999;56(1):306-317. doi: https://doi.org/10.1046/j.1523-1755.1999.00538.xRodriguez M, Caravaca F, Fernandez E, et al. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int. 1999;56(1):306-317. doi: https://doi.org/10.1046/j.1523-1755.1999.00538.xGoodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74(3):276-288. doi: https://doi.org/10.1038/sj.ki.5002287Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 2008;74(3):276-288. doi: https://doi.org/10.1038/sj.ki.5002287Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996;11(S3):130-135. doi: https://doi.org/10.1093/ndt/11.supp3.130Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996;11(S3):130-135. doi: https://doi.org/10.1093/ndt/11.supp3.130Егшатян Л.В., Мокрышева Н.Г., Рожинская Л.Я. Вторичный и третичный гиперпаратиреоз при хронической болезни почек // Остеопороз и остеопатии. — 2017. — Т. 20. — №2. — С. 63-68. doi: https://doi.org/10.14341/osteo2017263-68.Egshatyan LV, Mokrisheva NG, Rozhinskaya LY. Secondary and tertiary hyperparathyroidism in chronic kidney disease. Osteoporosis and Bone Diseases. 2017;20(2):63-68. (In Russ.). doi: https://doi.org/10.14341/osteo2017263-68.Егшатян Л.В., Рожинская Л.Я., Кузнецов Н.С., и др. Лечение вторичного гиперпаратиреоза, рефрактерного к альфакальцидолу, у пациентов, получающих заместительную почечную терапию программным гемодиализом // Эндокринная хирургия. — 2012. — Т. 6. — №2. — 27-41. doi: https://doi.org/10.14341/2306-3513-2012-2-27-41Egshatyan LV, Rozhinskaya LYa, Kuznetsov NS, et al. The treatment of secondary hyperparathyroidism in haemodialysis patients’ refractory to alfacalcidol. Endocrine Surgery. 2012;6(2):27-41. (In Russ.). doi: https://doi.org/10.14341/2306-3513-2012-2-27-41Slatopolsky E, Delmez JA. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. doi: https://doi.org/10.1016/j.kisu.2017.04.001Slatopolsky E, Delmez JA. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. doi: https://doi.org/10.1016/j.kisu.2017.04.001Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg. 1991;15(6):745-750. doi: https://doi.org/10.1007/BF01665309.Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg. 1991;15(6):745-750. doi: https://doi.org/10.1007/BF01665309.Gasparri G, Camandona M, Abbona GC, et al. Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Surg. 2001;233(1):65-69. doi: 10.1097/00000658-200101000-00011Gasparri G, Camandona M, Abbona GC, et al. Secondary and tertiary hyperparathyroidism: causes of recurrent disease after 446 parathyroidectomies. Ann Surg. 2001;233(1):65-69. doi: 10.1097/00000658-200101000-00011Dotzenrath C, Cupisti K, Goretzki E, et al. Operative treatment of renal autonomous hyperparathyroidism: cause of persistent or recurrent disease in 304 patients. Langenbeck’s Arch Surg. 2003;387(9-10):348-354. doi: https://doi.org/10.1007/s00423-002-0322-xDotzenrath C, Cupisti K, Goretzki E, et al. Operative treatment of renal autonomous hyperparathyroidism: cause of persistent or recurrent disease in 304 patients. Langenbeck’s Arch Surg. 2003;387(9-10):348-354. doi: https://doi.org/10.1007/s00423-002-0322-xWesterdahl J, Lindblom P, Valdemarsson S, et al. Risk factors for postoperative hypocalcemia after surgery for primary hyperparathyroidism. Arch Surg. 2000;135(2):142-147. doi: https://doi.org/10.1001/archsurg.135.2.142Westerdahl J, Lindblom P, Valdemarsson S, et al. Risk factors for postoperative hypocalcemia after surgery for primary hyperparathyroidism. Arch Surg. 2000;135(2):142-147. doi: https://doi.org/10.1001/archsurg.135.2.142Bergenfelz A, Jansson S, Mårtensson H, et al. Scandinavian Quality Register for Thyroid and Parathyroid Surgery: audit of surgery for primary hyperparathyroidism. Langenbeck’s Arch Surg. 2007;392(4):445-451. doi: https://doi.org/10.1007/s00423-006-0097-6Bergenfelz A, Jansson S, Mårtensson H, et al. Scandinavian Quality Register for Thyroid and Parathyroid Surgery: audit of surgery for primary hyperparathyroidism. Langenbeck’s Arch Surg. 2007;392(4):445-451. doi: https://doi.org/10.1007/s00423-006-0097-6Page C, Strunski V. Parathyroid risk in total thyroidectomy for bilateral, benign, multinodular goitre: report of 351 surgical cases. J Laryngol Otol. 2007;121(3):237-241. doi: https://doi.org/10.1017/S0022215106003501Page C, Strunski V. Parathyroid risk in total thyroidectomy for bilateral, benign, multinodular goitre: report of 351 surgical cases. J Laryngol Otol. 2007;121(3):237-241. doi: https://doi.org/10.1017/S0022215106003501Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab. 2019;104(11):5136-5147. doi: https://doi.org/10.1210/jc.2019-01010Mannstadt M, Clarke BL, Bilezikian JP, et al. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. J Clin Endocrinol Metab. 2019;104(11):5136-5147. doi: https://doi.org/10.1210/jc.2019-01010Palui R, Das RR, Roy A, et al. Parathyroid Hormone Replacement versus Oral Calcium and Active Vitamin D Supplementation in Hypoparathyroidism: A Meta-analysis. Indian J Endocrinol Metab. 2020;24(2):206-214. doi: https://doi.org/10.4103/ijem.IJEM_579_19Palui R, Das RR, Roy A, et al. Parathyroid Hormone Replacement versus Oral Calcium and Active Vitamin D Supplementation in Hypoparathyroidism: A Meta-analysis. Indian J Endocrinol Metab. 2020;24(2):206-214. doi: https://doi.org/10.4103/ijem.IJEM_579_19Tay Y-KD, Tabacco G, Cusano NE, et al. Therapy of Hypoparathyroidism With rhPTH(1–84): A Prospective, 8-Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab. 2019;104(11):5601-5610. doi: https://doi.org/10.1210/jc.2019-00893Tay Y-KD, Tabacco G, Cusano NE, et al. Therapy of Hypoparathyroidism With rhPTH(1–84): A Prospective, 8-Year Investigation of Efficacy and Safety. J Clin Endocrinol Metab. 2019;104(11):5601-5610. doi: https://doi.org/10.1210/jc.2019-00893Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate [Internet]. 2019. Available from: https://www.takeda.com/en-us/newsroom/news-releases/2019/takeda-issues-us-recall-of-natpara-parathyroid-hormone-for-injection-due-to-the-potential-for-rubber-particulate/ [cited 20.02.2022]Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate [Internet]. 2019. Available from: https://www.takeda.com/en-us/newsroom/news-releases/2019/takeda-issues-us-recall-of-natpara-parathyroid-hormone-for-injection-due-to-the-potential-for-rubber-particulate/ [cited 20.02.2022]Гребенникова Т.А., Ларина И.И., Белая Ж.Е., Рожинская Л.Я. Клинический случай применения терипаратида для лечения послеоперационного гипопаратиреоза с неконтролируемой гипокальциемией в сочетании с тяжелым остеопорозом // Остеопороз и остеопатии. — 2016. — Т. 19. — №3. — С. 37-40. doi: https://doi.org/10.14341/osteo2016337-40Grebennikova TA, Larina II, Belaya ZE, Rozhinskaya LY. Clinical case of teriparatide use for the treatment of postoperative hypoparathyroidism with uncontrolled hypocalcemia combined with severe osteoporosis. Osteoporosis and Bone Diseases. 2016;19(3):37-40. (In Russ.) doi: https://doi.org/10.14341/osteo2016337-40Bover J, Ureña-Torres P, Laiz Alonso AM, et al. Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. Nefrologia (Engl Ed). 2019;39(3):227-242. doi: https://doi.org/10.1016/j.nefro.2018.10.009Bover J, Ureña-Torres P, Laiz Alonso AM, et al. Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. Nefrologia (Engl Ed). 2019;39(3):227-242. doi: https://doi.org/10.1016/j.nefro.2018.10.009Fuss CT, Burger-Stritt S, Horn S, et al. Continuous rhPTH (1–34) treatment in chronic hypoparathyroidism. Endocrinol Diabetes Metab Case Reports. 2020;2020(1):1-59. doi: https://doi.org/10.1530/EDM-20-0009Fuss CT, Burger-Stritt S, Horn S, et al. Continuous rhPTH (1–34) treatment in chronic hypoparathyroidism. Endocrinol Diabetes Metab Case Reports. 2020;2020(1):1-59. doi: https://doi.org/10.1530/EDM-20-0009Barreto DV, Barreto F de C, de Carvalho AB, et al. Association of Changes in Bone Remodeling and Coronary Calcification in Hemodialysis Patients: A Prospective Study. Am J Kidney Dis. 2008;52(6):1139-1150. doi: https://doi.org/10.1053/j.ajkd.2008.06.024Barreto DV, Barreto F de C, de Carvalho AB, et al. Association of Changes in Bone Remodeling and Coronary Calcification in Hemodialysis Patients: A Prospective Study. Am J Kidney Dis. 2008;52(6):1139-1150. doi: https://doi.org/10.1053/j.ajkd.2008.06.024Brandi ML. Hypoparathyroidism: the hormone replacement therapy is close. Expert Rev Endocrinol Metab. 2012;7(3):255-257. doi: https://doi.org/10.1586/eem.12.14Brandi ML. Hypoparathyroidism: the hormone replacement therapy is close. Expert Rev Endocrinol Metab. 2012;7(3):255-257. doi: https://doi.org/10.1586/eem.12.14Rejnmark L, Sikjaer T, Underbjerg L, Mosekilde L. PTH replacement therapy of hypoparathyroidism. Osteoporos Int. 2013;24(5):1529-1536. doi: https://doi.org/10.1007/s00198-012-2230-4Rejnmark L, Sikjaer T, Underbjerg L, Mosekilde L. PTH replacement therapy of hypoparathyroidism. Osteoporos Int. 2013;24(5):1529-1536. doi: https://doi.org/10.1007/s00198-012-2230-4Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45(6):1053-1058. doi: https://doi.org/10.1016/j.bone.2009.07.091.Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45(6):1053-1058. doi: https://doi.org/10.1016/j.bone.2009.07.091.Eriksen EF, Keaveny TM, Gallagher ER, Krege JH. Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis. Bone. 2014;67(5):246-256. doi: https://doi.org/10.1016/j.bone.2014.07.014Eriksen EF, Keaveny TM, Gallagher ER, Krege JH. Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis. Bone. 2014;67(5):246-256. doi: https://doi.org/10.1016/j.bone.2014.07.014Fujihara R, Mashiba T, Yoshitake S, et al. Weekly teriparatide treatment increases vertebral body strength by improving cortical shell architecture in ovariectomized cynomolgus monkeys. Bone. 2019;121(5):80-88. doi: https://doi.org/10.1016/j.bone.2019.01.006Fujihara R, Mashiba T, Yoshitake S, et al. Weekly teriparatide treatment increases vertebral body strength by improving cortical shell architecture in ovariectomized cynomolgus monkeys. Bone. 2019;121(5):80-88. doi: https://doi.org/10.1016/j.bone.2019.01.006Chen P, Jerome CP, Burr DB, et al. Interrelationships Between Bone Microarchitecture and Strength in Ovariectomized Monkeys Treated With Teriparatide. J Bone Miner Res. 2007;22(6):841-848. doi: https://doi.org/10.1359/jbmr.070310Chen P, Jerome CP, Burr DB, et al. Interrelationships Between Bone Microarchitecture and Strength in Ovariectomized Monkeys Treated With Teriparatide. J Bone Miner Res. 2007;22(6):841-848. doi: https://doi.org/10.1359/jbmr.070310Cejka D, Kodras K, Bader T, Haas M. Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1–34): A Pilot Study. Kidney Blood Press Res. 2010;33(3):221-226. doi: https://doi.org/10.1159/000316708Cejka D, Kodras K, Bader T, Haas M. Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1–34): A Pilot Study. Kidney Blood Press Res. 2010;33(3):221-226. doi: https://doi.org/10.1159/000316708Sumida K, Ubara Y, Hoshino J, et al. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int. 2016;27(4):1441-1450. doi: https://doi.org/10.1007/s00198-015-3377-6Sumida K, Ubara Y, Hoshino J, et al. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study. Osteoporos Int. 2016;27(4):1441-1450. doi: https://doi.org/10.1007/s00198-015-3377-6Kleerekoper M, Greenspan SL, Lewiecki EM, et al. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. J Bone Joint Surg Am. 2014;96(11):e90. doi: https://doi.org/10.2106/JBJS.L.01757.Kleerekoper M, Greenspan SL, Lewiecki EM, et al. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. J Bone Joint Surg Am. 2014;96(11):e90. doi: https://doi.org/10.2106/JBJS.L.01757.Chang H, Knothe Tate ML. Concise review: the periosteum: tapping into a reservoir of clinically useful progenitor cells. Stem Cells Transl Med. 2012;1(6):480-491. doi: https://doi.org/10.5966/sctm.2011-0056Chang H, Knothe Tate ML. Concise review: the periosteum: tapping into a reservoir of clinically useful progenitor cells. Stem Cells Transl Med. 2012;1(6):480-491. doi: https://doi.org/10.5966/sctm.2011-0056Frey SP, Jansen H, Doht S, et al. Immunohistochemical and Molecular Characterization of the Human Periosteum. Sci World J. 2013;2013(4):1-8. doi: https://doi.org/10.1155/2013/341078Frey SP, Jansen H, Doht S, et al. Immunohistochemical and Molecular Characterization of the Human Periosteum. Sci World J. 2013;2013(4):1-8. doi: https://doi.org/10.1155/2013/341078Allen MR, Hock JM, Burr DB. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone. 2004;35(5):1003-1012. doi: https://doi.org/10.1016/j.bone.2004.07.014Allen MR, Hock JM, Burr DB. Periosteum: biology, regulation, and response to osteoporosis therapies. Bone. 2004;35(5):1003-1012. doi: https://doi.org/10.1016/j.bone.2004.07.014Cohen A, Boutroy S, Stein E, et al. High resolution peripheral quantitative computed tomography (HRpQCT) detects improved trabecular volumetric BMD and microarchitecture in premenopausal women with idiopathic osteoporosis treated with teriparatide. J Bone Min Res. 2011;S1:S359-S360. doi: https://doi.org/10.1002/jbmr.564Cohen A, Boutroy S, Stein E, et al. High resolution peripheral quantitative computed tomography (HRpQCT) detects improved trabecular volumetric BMD and microarchitecture in premenopausal women with idiopathic osteoporosis treated with teriparatide. J Bone Min Res. 2011;S1:S359-S360. doi: https://doi.org/10.1002/jbmr.564Kawagishi T, Nishizawa Y, Konishi T, et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int. 1995;48(3):820-826. doi: https://doi.org/10.1038/ki.1995.356Kawagishi T, Nishizawa Y, Konishi T, et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int. 1995;48(3):820-826. doi: https://doi.org/10.1038/ki.1995.356Cannata-Andia JB, Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrol Dial Transplant. 2002;17(S11):16-19. doi: https://doi.org/10.1093/ndt/17.suppl_11.16Cannata-Andia JB, Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrol Dial Transplant. 2002;17(S11):16-19. doi: https://doi.org/10.1093/ndt/17.suppl_11.16Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98(13):1302-1306. doi: https://doi.org/10.1161/01.cir.98.13.1302Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98(13):1302-1306. doi: https://doi.org/10.1161/01.cir.98.13.1302Cardús A, Panizo S, Parisi E, et al. Differential Effects of Vitamin D Analogs on Vascular Calcification. J Bone Miner Res. 2007;22(6):860-866. doi: https://doi.org/10.1359/jbmr.070305Cardús A, Panizo S, Parisi E, et al. Differential Effects of Vitamin D Analogs on Vascular Calcification. J Bone Miner Res. 2007;22(6):860-866. doi: https://doi.org/10.1359/jbmr.070305Wolisi GO, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005;18(4):307-314. doi: https://doi.org/10.1111/j.1525-139X.2005.18407.xWolisi GO, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005;18(4):307-314. doi: https://doi.org/10.1111/j.1525-139X.2005.18407.xЕгшатян Л.В., Рожинская Л.Я., Кузнецов Н.С. Сосудистая кальцификация и возможности ее коррекции у пациентов с терминальной стадией хронической болезни почек // Эффективная фармакотерапия. — 2011. — С. 40-46.Egshatyan LV, Rozhinskaya LYa, Kuzneczov NS. Sosudistaya kal`czifikacziya i vozmozhnosti ee korrekczii u paczientov s terminal`noj stadiej khronicheskoj bolezni pochek. E`ffektivnaya farmakoterapiya. 2011:40-46. (In Russ.).Shao J-S, Cheng S-L, Charlton-Kachigian N, et al. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003;278(50):50195-50202. doi: https://doi.org/10.1074/jbc.M308825200.Shao J-S, Cheng S-L, Charlton-Kachigian N, et al. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003;278(50):50195-50202. doi: https://doi.org/10.1074/jbc.M308825200.Tashjian AH, Chabner BA. Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1‐34 in the Treatment of Osteoporosis in Men and Postmenopausal Women. J Bone Miner Res. 2002;17(7):1151-1161. doi: https://doi.org/10.1359/jbmr.2002.17.7.1151Tashjian AH, Chabner BA. Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1‐34 in the Treatment of Osteoporosis in Men and Postmenopausal Women. J Bone Miner Res. 2002;17(7):1151-1161. doi: https://doi.org/10.1359/jbmr.2002.17.7.1151Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312-321. doi: https://doi.org/10.1080/01926230252929882Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312-321. doi: https://doi.org/10.1080/01926230252929882Burr DB, Hirano T, Turner CH, et al. Intermittently Administered Human Parathyroid Hormone(1-34) Treatment Increases Intracortical Bone Turnover and Porosity Without Reducing Bone Strength in the Humerus of Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2001;16(1):157-165. doi: https://doi.org/10.1359/jbmr.2001.16.1.157Burr DB, Hirano T, Turner CH, et al. Intermittently Administered Human Parathyroid Hormone(1-34) Treatment Increases Intracortical Bone Turnover and Porosity Without Reducing Bone Strength in the Humerus of Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2001;16(1):157-165. doi: https://doi.org/10.1359/jbmr.2001.16.1.157Winer KK, Sinaii N, Reynolds J, et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010;95(6):2680-2688. doi: https://doi.org/10.1210/jc.2009-2464Winer KK, Sinaii N, Reynolds J, et al. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010;95(6):2680-2688. doi: https://doi.org/10.1210/jc.2009-2464Nishikawa A, Yoshiki F, Taketsuna M, et al. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging. 2016;11(1):1653-1659. doi: https://doi.org/10.2147/CIA.S120175Nishikawa A, Yoshiki F, Taketsuna M, et al. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging. 2016;11(1):1653-1659. doi: https://doi.org/10.2147/CIA.S120175

The authors declare that there are no conflicts of interest present.